IRWD Ironwood Pharmaceuticals, Inc.

18.62
-0.45  -2%
Previous Close 19.07
Open 19.04
Price To book 95.35
Market Cap 2.77B
Shares 148,616,000
Volume 997,106
Short Ratio 8.97
Av. Daily Volume 1,479,570

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due 2H 2017.
IW-1973
Type 2 diabetes
Phase 2a data due 2H 2017.
IW-1973
Type 2 diabetes
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Phase 2b data released December 22, 2016. Phase 3 trials to be initiated in 2H 2017.
Linaclotide Colonic Release
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2a data released April 2016. Development to be discontinued due to disappointing data
IW-9179
Gastroparesis
Phase 2b data due mid-2017.
IW-3718
Gastroesophageal reflux disease (GERD)

Latest News

  1. Allergan's Irritable Bowel Drug Viberzi Approved in Canada
  2. Edited Transcript of IRWD earnings conference call or presentation 8-May-17 12:30pm GMT
  3. Ironwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : May 11, 2017
  4. Ironwood Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference
  5. Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : May 10, 2017
  6. Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide’s Effect on Pain at Digestive Disease Week® 2017
  7. Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss
  8. Ironwood reports 1Q loss
  9. Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update
  10. Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call
  11. Ironwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and IW-1701 at Digestive Disease Week® 2017
  12. Ironwood Pharmaceuticals to Host First Quarter 2017 Investor Update Call
  13. Are Options Traders Betting on a Big Move in Ironwood Pharmaceuticals (IRWD) Stock?
  14. Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5)
  15. Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : April 6, 2017
  16. Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer
  17. ETFs with exposure to Ironwood Pharmaceuticals, Inc. : April 5, 2017
  18. Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
  19. Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  20. Synergy Pharmaceuticals: Approval, Now What?